Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic pooled human faecal microbiota transplant
- Development stage
- Unknown
- Lead developer
- Faculty Hospital Kralovske Vinohrady
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Rectal
01
Overview
Allogeneic pooled human faecal microbiota transplant (FMT) is a microbiome-based therapeutic intervention involving the transfer of a processed suspension of stool from multiple healthy donors into the gastrointestinal tract of a recipient. By pooling samples from multiple donors, the therapy aims to increase microbial diversity and standardize the therapeutic potency of the transplant compared to single-donor preparations. In the context of post-antibiotic diarrhea (PAD) in critically ill patients, the transplant is intended to restore a healthy microbial balance, outcompete opportunistic pathogens, and prevent complications such as treatment failure or recurrence. This specific preparation is being evaluated in a Phase IV clinical trial sponsored by Fakultni Nemocnice Kralovske Vinohrady to assess its efficacy as a first-line therapy in the intensive care setting.
- Other names
- Faecal BacteriotherapyFecal Microbiota TransplantFMTallogeneic pooled FMT
Beyond the preview
Go deeper on allogeneic pooled human faecal microbiota transplant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic pooled human faecal microbiota transplant.